Racism in Drug Testing.
| Autor: | Hubbard JA; Hubbard Lab Consulting, 6016 Hawthorn Drive, Coraopolis, PA 15275, USA. Electronic address: jhubbard@hubbardlabconsulting.com., Johnson-Davis KL; Department of Pathology, University of Utah Health, Salt Lake City, UT, USA; ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinics in laboratory medicine [Clin Lab Med] 2024 Dec; Vol. 44 (4), pp. 607-617. Date of Electronic Publication: 2024 Sep 20. |
| DOI: | 10.1016/j.cll.2024.07.006 |
| Abstrakt: | Racial disparities in drug testing for substance-use disorders underscore systemic inequalities. Studies reveal that minority groups, particularly Black and Hispanic Americans, are disproportionately targeted for drug testing despite similar rates of drug use across racial lines. Such bias impacts employment opportunities, legal outcomes, and access to treatment. The overrepresentation of minorities in drug testing reflects broader societal prejudices, leading to a cycle of discrimination and marginalization. Addressing these disparities requires a multifaceted approach, including policy reform, increased awareness of implicit biases, and equitable health care practices to ensure fair treatment of all individuals struggling with substance-use disorders. Competing Interests: Disclosure The authors have no financial or commercial conflicts of interest to disclose. No funding was provided for this article. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|